Core Viewpoint - Lee's Pharmaceutical Holdings Limited (00950) experienced a significant stock price increase, rising over 21% at the close, with a current increase of 16.02% to HKD 21, supported by strong mid-term performance and new product approvals [1] Financial Performance - The company reported a revenue of HKD 695 million, reflecting a year-on-year increase of 5.5%, driven by robust sales performance across its product portfolio [1] - For the first half of 2025, the profit attributable to shareholders was HKD 67.185 million, marking a 7.5% increase compared to the previous year [1] - Earnings per share stood at HKD 0.1141 [1] Product Development - Lee's Pharmaceutical announced that its subsidiary, Zhaoke Pharmaceutical, received approval for a new indication for the anti-PD-L1 monoclonal antibody, Socazolimab, for use in combination with chemotherapy as a first-line treatment for extensive-stage small cell lung cancer [1] - This approval represents the second indication for Socazolimab, following its initial conditional approval for the treatment of recurrent or metastatic cervical cancer [1]
李氏大药厂尾盘涨超21% 上半年纯利增长7.5% 旗下PD-L1单抗国内近日获批上市